OLMA insider ownership: who sold, why, and what they still hold

What stands out

Four insiders sold $23.0M with no disclosed plan: Ian Clark ($7.9M), Naseem Zojwalla ($7.5M) and David Myles ($4.7M), plus 1 more. The filings don't state a reason.Ian Clark: largest such sale, Dec 19, 2025 · Naseem Zojwalla: largest such sale, Dec 22, 2025 · David Myles: largest such sale, Jan 13, 2026

A share of stake is shown for 0 of the 6 officers and directors who sold. 17 are left out

Left out: Walmsley Graham, Cyrus Harmon, David Myles, Shane Kovacs, Andrew Rappaport, Sean Bohen, Naseem Zojwalla, Sasha Austin, Cynthia Butitta, Ian Clark, Sandra Horning, Gorjan Hrustanovic, Yi Larson, Scott Garland, Shawnte Mitchell, Prakash Raman and Jason O'Byrne (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Ian Clark

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$7.9MNo plan disclosed

Naseem Zojwalla

Chief Medical Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$7.5MNo plan disclosed

David Myles

Ch. Discov. & Non-Clin Dev Off

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.7MNo plan disclosed

Shane Kovacs

Ch. Operating & Financial Off.

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$3.0MNo plan disclosed

Shawnte Mitchell

Chief Legal Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$952KNo plan disclosed

All 6 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

No plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Jul 24, 2026Cyrus Harmon sold 13K shares ($146K) with no plan disclosed.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Cyrus Harmon Director	12,500	$11.71	n/a	n/a	Jul 24, 2026	Jul 27, 2026

Outside holders, reported separately

BVF PARTNERS L P/IL and Walmsley Graham reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Olema Pharmaceuticals, Inc. CEO selling stock?

No. Sean Bohen reported no open-market sales in the past 12 months.

Why are Olema Pharmaceuticals, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 0% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 100% had no disclosed plan. A trading plan schedules sales in advance.

Are any Olema Pharmaceuticals, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold6 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Ian Clark Director	$7.9M 265K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Naseem Zojwalla Chief Medical Officer	$7.5M 270K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
David Myles Ch. Discov. & Non-Clin Dev Off	$4.7M 161K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Shane Kovacs Ch. Operating & Financial Off.	$3.0M 104K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Shawnte Mitchell Chief Legal Officer	$952K 40K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Cyrus Harmon Director	$744K 41K shares	Not confirmed share of stake is being verified. Why	No plan disclosed

Board members representing outside shareholders, reported separately: Walmsley Graham. Details

Outside holder, reported separately: BVF PARTNERS L P/IL (an outside shareholder, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 17 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

Walmsley Graham

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Walmsley Graham are complete.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Walmsley Graham

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Walmsley Graham are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
23,000	$12.36	Jun 14, 2034	$0
24,150	$4.08	Jun 11, 2035	$184K
29,500	$9.51	Jun 18, 2036	$65K

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Cyrus Harmon

Director

n/a

−41K

n/a

Vesting, gifts, unvested awards and holding lines for Cyrus Harmon

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Cyrus Harmon are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
23,000	$12.36	Jun 14, 2034	$0
24,150	$4.08	Jun 11, 2035	$184K
29,500	$9.51	Jun 18, 2036	$65K

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

David Myles

Ch. Discov. & Non-Clin Dev Off

n/a

−161K

n/a

Vesting, gifts, unvested awards and holding lines for David Myles

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Myles are complete; balances and unit counts will be added when the check is finished.

−9Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
50,000	$4.87	Jan 31, 2033	$342K
195,000	$15.25	Jan 31, 2034	$0
205,000	$4.37	Feb 27, 2035	$1.5M
250,000	$25.65	Feb 1, 2036	$0
106,250	$25.65	Feb 1, 2036	$0

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Shane Kovacs

Ch. Operating & Financial Off.

n/a

−104K

n/a

Vesting, gifts, unvested awards and holding lines for Shane Kovacs

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Shane Kovacs are complete; balances and unit counts will be added when the check is finished.

−300Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
162,000	$7.02	Jan 31, 2032	$760K
304,500	$15.25	Jan 31, 2034	$0
320,000	$4.37	Feb 27, 2035	$2.4M

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Andrew Rappaport

Director

n/a

Vesting, gifts, unvested awards and holding lines for Andrew Rappaport

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Andrew Rappaport are complete; balances and unit counts will be added when the check is finished.

−36Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
23,000	$12.36	Jun 14, 2034	$0
24,150	$4.08	Jun 11, 2035	$184K
29,500	$9.51	Jun 18, 2036	$65K

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Sean Bohen

President and CEO, Director

n/a

Vesting, gifts, unvested awards and holding lines for Sean Bohen

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sean Bohen are complete; balances and unit counts will be added when the check is finished.

−8.5Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
621,500	$15.25	Jan 31, 2034	$0
650,000	$4.37	Feb 27, 2035	$4.8M
850,000	$25.65	Feb 1, 2036	$0
275,000	$25.65	Feb 1, 2036	$0

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Naseem Zojwalla

Chief Medical Officer

n/a

−270K

n/a

Vesting, gifts, unvested awards and holding lines for Naseem Zojwalla

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Naseem Zojwalla are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
156,818	$7.02	Jan 31, 2032	$736K
112,840	$4.87	Jan 31, 2033	$772K
112,182	$15.25	Jan 31, 2034	$0
205,000	$4.37	Feb 27, 2035	$1.5M
250,000	$25.65	Feb 1, 2036	$0
106,250	$25.65	Feb 1, 2036	$0

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Sasha Austin

VP of Finance and Controller

n/a

Vesting, gifts, unvested awards and holding lines for Sasha Austin

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sasha Austin are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,000	$2.44	Jan 24, 2031	$19K
3,000	$2.44	Aug 31, 2031	$28K
13,000	$2.44	Jan 31, 2032	$121K
6,500	$4.87	Jan 31, 2033	$44K
17,500	$3.49	Apr 2, 2033	$144K
51,000	$15.25	Jan 31, 2034	$0
45,000	$4.37	Feb 27, 2035	$330K
29,250	$25.65	Feb 1, 2036	$0

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Cynthia Butitta

Director

n/a

Vesting, gifts, unvested awards and holding lines for Cynthia Butitta

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Cynthia Butitta are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
23,000	$12.36	Jun 14, 2034	$0
24,150	$4.08	Jun 11, 2035	$184K
29,500	$9.51	Jun 18, 2036	$65K

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Ian Clark

Director

n/a

−265K

n/a

Vesting, gifts, unvested awards and holding lines for Ian Clark

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ian Clark are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
23,000	$12.36	Jun 14, 2034	$0
12,080	$4.08	Jun 11, 2035	$92K
29,500	$9.51	Jun 18, 2036	$65K

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Sandra Horning

Director

n/a

Vesting, gifts, unvested awards and holding lines for Sandra Horning

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sandra Horning are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
23,000	$12.36	Jun 14, 2034	$0
24,150	$4.08	Jun 11, 2035	$184K
29,500	$9.51	Jun 18, 2036	$65K

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Gorjan Hrustanovic

Director

n/a

Vesting, gifts, unvested awards and holding lines for Gorjan Hrustanovic

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Gorjan Hrustanovic are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
23,000	$12.36	Jun 14, 2034	$0
24,150	$4.08	Jun 11, 2035	$184K
29,500	$9.51	Jun 18, 2036	$65K

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Yi Larson

Director

n/a

Vesting, gifts, unvested awards and holding lines for Yi Larson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Yi Larson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
23,000	$12.36	Jun 14, 2034	$0
24,150	$4.08	Jun 11, 2035	$184K
29,500	$9.51	Jun 18, 2036	$65K

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Scott Garland

Director

n/a

Vesting, gifts, unvested awards and holding lines for Scott Garland

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Scott Garland are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
21,520	$10.54	Oct 15, 2033	$25K
14,347	$10.54	Oct 15, 2033	$17K
23,000	$12.36	Jun 14, 2034	$0
24,150	$4.08	Jun 11, 2035	$184K
29,500	$9.51	Jun 18, 2036	$65K

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Shawnte Mitchell

Chief Legal Officer

n/a

−40K

n/a

Vesting, gifts, unvested awards and holding lines for Shawnte Mitchell

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Shawnte Mitchell are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
410,000	$4.37	Feb 27, 2035	$3.0M
220,000	$25.65	Feb 1, 2036	$0
56,250	$25.65	Feb 1, 2036	$0

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Prakash Raman

Director

n/a

Vesting, gifts, unvested awards and holding lines for Prakash Raman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Prakash Raman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,911	$14.59	Apr 27, 2036	$0
24,150	$14.59	Apr 27, 2036	$0
29,500	$9.51	Jun 18, 2036	$65K

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Jason O'Byrne

Chief Financial Officer

n/a

Vesting, gifts, unvested awards and holding lines for Jason O'Byrne

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jason O'Byrne are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
650,000	$10.56	Aug 31, 2036	$750K

Estimate: options held × ($11.71 − strike price), using the most recent insider trade price on Form 4 (Jul 24, 2026), not a market close.

Holdings and share of stake for Olema Pharmaceuticals, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$24.7M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $24.7M across 880,501 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

No plan disclosed · $24.7M

Sales with no 10b5-1 plan and no tax reference in the filing. $7.9M of it is Ian Clark. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Ian Clark, Dec 19, 2025

Charitable gifts · 44K shares

Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Ian Clark Director	265K	$7.9M	0%	32%	Dec 19, 2025 to Dec 19, 2025
Naseem Zojwalla Chief Medical Officer	270K	$7.5M	0%	30%	Dec 19, 2025 to Dec 23, 2025
David Myles Ch. Discov. & Non-Clin Dev Off	161K	$4.7M	0%	19%	Dec 19, 2025 to Jan 14, 2026
Shane Kovacs Ch. Operating & Financial Off.	104K	$3.0M	0%	12%	Jan 13, 2026 to Jan 15, 2026
Shawnte Mitchell Chief Legal Officer	40K	$952K	0%	4%	Mar 3, 2026 to Mar 4, 2026
Cyrus Harmon Director	41K	$744K	0%	3%	Dec 22, 2025 to Jul 24, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$0	$0	$0	$0
Dec 2025	$17.0M	$0	$0	$17.0M
Jan 2026	$6.5M	$0	$0	$6.5M
Feb 2026	$0	$0	$0	$0
Mar 2026	$952K	$0	$0	$952K
Apr 2026	$0	$0	$0	$0
May 2026	$0	$0	$0	$0
Jun 2026	$0	$0	$0	$0
Jul 2026	$291K	$0	$0	$291K
Aug 2026	$0	$0	$0	$0
Sep 2026	$0	$0	$0	$0
Oct 2026	$0	$0	$0	$0

Board members representing outside shareholders (1)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member	Held Oct 16, 2025	Sold	Held Oct 16, 2026	Still held
Walmsley Graham ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Walmsley Graham are complete. Director	n/a	0	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Walmsley Graham Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Walmsley Graham are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)

Is this normal? Selling year by year4 earlier years to compare with

More than usual: $24.7M sold, after almost none in the past 4 years. 6 insiders sold; the average is 4 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 16, 2026 Latest 12 months	881K	6	$24.7M
Oct 16, 2025 1 year earlier	240K	5	$2.1M
Oct 16, 2024 2 years earlier	353K	5	$4.5M
Oct 17, 2023 3 years earlier	105K	2	$1.1M
Oct 17, 2022 4 years earlier	66K	3	$1.3M
Oct 17, 2021 5 years earlier · filings don't cover the whole year	142K	3	$3.6M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty17 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Olema Pharmaceuticals, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology244 filings on record, 35 filed in the 12-month period, and how we read them

All 244 Forms 3, 4 and 5 on record for Olema Pharmaceuticals, Inc. (SEC CIK 1750284), filed from Nov 18, 2020 to Sep 2, 2026; 35 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (8)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Bain Capital Life Sciences Investors, LLC	Jan 13, 2025	4,300,000 shares, last reported balance as of Jan 10, 2025
Paradigm Biocapital Advisors LP	Aug 5, 2024	5,503,600 shares, last reported balance as of Aug 1, 2024
Kinney Horn	Feb 2, 2023	2,458 shares, last reported balance as of Mar 10, 2022
John Moriarty	Feb 2, 2023	No balance on record
Peter Kushner	Feb 3, 2022	1,431,672 shares, last reported balance as of Nov 23, 2020
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.	Nov 24, 2020	1,725,406 shares, last reported balance as of Nov 23, 2020
Cormorant Asset Management, LP	Nov 23, 2020	3,270,544 shares, last reported balance as of Nov 23, 2020
Frank McCormick	Nov 23, 2020	275,373 shares, last reported balance as of Nov 23, 2020

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Olema Pharmaceuticals, Inc. insiders sold $24.7M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Olema Pharmaceuticals, Inc. CEO selling stock?

Why are Olema Pharmaceuticals, Inc. insiders selling?

Are any Olema Pharmaceuticals, Inc. insiders buying?

The evidence

No plan disclosed · $24.7M

Charitable gifts · 44K shares

Sales by month